Syntax Research, Inc. Regeneron Pharmaceuticals, Inc. Transaction History
Syntax Research, Inc.
- $126 Billion
- Q2 2024
A detailed history of Syntax Research, Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Syntax Research, Inc. holds 345 shares of REGN stock, worth $255,303. This represents 0.29% of its overall portfolio holdings.
Number of Shares
345
Previous 345
-0.0%
Holding current value
$255,303
Previous $332 Million
9.2%
% of portfolio
0.29%
Previous 0.25%
Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,535Shares Held
83.8MCall Options Held
1.22MPut Options Held
1.51M-
Vanguard Group Inc Valley Forge, PA9.32MShares$6.9 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$6.25 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.49MShares$5.54 Billion0.65% of portfolio
-
State Street Corp Boston, MA4.9MShares$3.63 Billion0.21% of portfolio
-
Capital World Investors Los Angeles, CA4.3MShares$3.18 Billion0.72% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $79.3B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...